Haoyuan Pharmaceutical Bird's purchase of assets and raising supporting funds was suspended for review

On July 31, 2022, Haoyuan Pharmaceutical (688131.SH) of Science and Technology Board Company issued an announcement on receiving the notice of receiving the suspension of the Shanghai Stock Exchange.

Shanghai Haoyuan Pharmaceutical Co., Ltd. (hereinafter referred to as "Company") issued shares and payment cash to purchase assets and raised supporting funds and affiliated transaction projects (hereinafter referred to as "this transaction") obtained Shanghai Securities on July 14, 2022 Exchange acceptance.

The relevant securities service agencies hired by the company were investigated by the China Securities Regulatory Commission. According to the relevant provisions of Article 51 (4) of Article 51 (4) of the Shanghai Stock Exchange Science and Technology Innovation Board, Shanghai Securities Securities The exchange suspended the transaction review on July 29, 2022.

The company and intermediary agencies will strictly complete the preparations required for the restoration of the review in accordance with the relevant laws and the requirements of the Shanghai Stock Exchange, and submit the application for the recovery review as soon as possible. The company will perform the information disclosure obligation in a timely manner according to the progress of the relevant matters.

The company has nothing to do with the above -mentioned intermediary agency's investigation. The suspension review of this transaction will not have a significant adverse effect on the company's production and operation activities.

The company's transaction needs to be approved by the Shanghai Stock Exchange and reported to the China Securities Supervision and Administration Commission to register. There is still uncertainty. According to the progress of related matters, the company will fulfill the obligation of information disclosure in a timely manner.

- END -